coronavirus vaccine later this month. The drugmaker could file for US emergency use authorization in early December, according to Reuters.It was too early to guess how effective Moderna's vaccine could be, Chief executive officer Stephane Bancel said at a Credit Suisse conference.
The world would have to wait for more data to understand whether use of a particular vaccine would be more widespread, Bancel said.For Moderna’s shot, an interim analysis will be triggered after 53 volunteers from its roughly 40,000-person study come down with a COVID-19 infection.
The participants are split between those vaccinated and those getting a placebo, and volunteers will be followed for a safety analysis.